Boston Scientific stock faces weaker fourth-quarter outlook

Boston Scientific reported slower third-quarter growth on October 28, 2026, and lowered its near-term sales outlook after an August cybersecurity incident disrupted operations. According to the company's official results release, net sales for the period ended September 30 reached USD 5.138 billion, up 1.5 percent from the prior-year quarter.

Q4 Outlook Turns Negative

Boston Scientific expects reported and organic fourth-quarter sales to decline between 1 percent and 3 percent year over year. Adjusted earnings per share is forecast at USD 0.77 to USD 0.79. For full-year 2026, management projects reported sales growth of approximately 4.25 percent, organic growth of approximately 3.75 percent and adjusted EPS of USD 3.16 to USD 3.18.

The company said adjusted EPS fell to USD 0.73 from USD 0.75 a year earlier, while GAAP EPS declined to USD 0.40 from USD 0.51. The reported result included impairment, restructuring and litigation-related charges, whereas adjusted EPS excludes specified charges and credits.

Pipeline Offers Longer-Term Support

Growth varied across the portfolio. Cardiovascular sales rose 1.9 percent, while MedSurg sales increased 0.6 percent. Boston Scientific also began enrolling patients in the Elite AF trial for the next-generation WATCHMAN Elite device and received U.S. clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter.

The company entered a strategic collaboration with Heartflow on AI-assisted planning for coronary interventions. For investors, the key test is whether these programs can offset near-term operational pressure and restore a stronger growth pace.

Boston Scientific stock traded at 38.55 euros on Lang & Schwarz at 4:36 p.m. CET on Monday, November 2, 2026. The quote was 2.96 percent above the 37.44-euro quote in the prior report published earlier that day at 10:47 a.m. CET; this period comparison uses separate timestamps from a daily market comparison.

Use the real-time quote of Boston Scientific stock for the latest trading indication.

Current market developments can be followed through S&P 500 market reports.

See more news and analyses on Boston Scientific stock.